© Reuters. Amgen teams up with Boston Children’s Hospital to identify new pain targets
- Amgen (NASDAQ:AMGN) enters into a neuroscience research collaboration with Boston Children’s Hospital’s Division of Pain Medicine that will leverage genetic analyses to identify new pain targets. The one-year partnership will focus on patients with genetic abnormalities of pain sensitivity.
- Financial terms are not disclosed.
- Now read: Your Daily Pharma Scoop: AcelRx Second Chance, Aerie Rhopressa Success, Aratana ENTYCE Launch